134 related articles for article (PubMed ID: 22079732)
1. Beta-carotene antioxidant use during radiation therapy and prostate cancer outcome in the Physicians' Health Study.
Margalit DN; Kasperzyk JL; Martin NE; Sesso HD; Gaziano JM; Ma J; Stampfer MJ; Mucci LA
Int J Radiat Oncol Biol Phys; 2012 May; 83(1):28-32. PubMed ID: 22079732
[TBL] [Abstract][Full Text] [Related]
2. Supplemental and dietary vitamin E, beta-carotene, and vitamin C intakes and prostate cancer risk.
Kirsh VA; Hayes RB; Mayne ST; Chatterjee N; Subar AF; Dixon LB; Albanes D; Andriole GL; Urban DA; Peters U;
J Natl Cancer Inst; 2006 Feb; 98(4):245-54. PubMed ID: 16478743
[TBL] [Abstract][Full Text] [Related]
3. A randomized trial of antioxidant vitamins to prevent second primary cancers in head and neck cancer patients.
Bairati I; Meyer F; Gélinas M; Fortin A; Nabid A; Brochet F; Mercier JP; Têtu B; Harel F; Mâsse B; Vigneault E; Vass S; del Vecchio P; Roy J
J Natl Cancer Inst; 2005 Apr; 97(7):481-8. PubMed ID: 15812073
[TBL] [Abstract][Full Text] [Related]
4. Larger maximum tumor diameter at radical prostatectomy is associated with increased biochemical failure, metastasis, and death from prostate cancer after salvage radiation for prostate cancer.
Johnson SB; Hamstra DA; Jackson WC; Zhou J; Foster B; Foster C; Song Y; Li D; Palapattu GS; Kunju L; Mehra R; Sandler H; Feng FY
Int J Radiat Oncol Biol Phys; 2013 Oct; 87(2):275-81. PubMed ID: 23886418
[TBL] [Abstract][Full Text] [Related]
5. Associations between alpha-tocopherol, beta-carotene, and retinol and prostate cancer survival.
Watters JL; Gail MH; Weinstein SJ; Virtamo J; Albanes D
Cancer Res; 2009 May; 69(9):3833-41. PubMed ID: 19383902
[TBL] [Abstract][Full Text] [Related]
6. Short-term androgen suppression and radiotherapy versus intermediate-term androgen suppression and radiotherapy, with or without zoledronic acid, in men with locally advanced prostate cancer (TROG 03.04 RADAR): 10-year results from a randomised, phase 3, factorial trial.
Denham JW; Joseph D; Lamb DS; Spry NA; Duchesne G; Matthews J; Atkinson C; Tai KH; Christie D; Kenny L; Turner S; Gogna NK; Diamond T; Delahunt B; Oldmeadow C; Attia J; Steigler A
Lancet Oncol; 2019 Feb; 20(2):267-281. PubMed ID: 30579763
[TBL] [Abstract][Full Text] [Related]
7. Design of Physicians' Health Study II--a randomized trial of beta-carotene, vitamins E and C, and multivitamins, in prevention of cancer, cardiovascular disease, and eye disease, and review of results of completed trials.
Christen WG; Gaziano JM; Hennekens CH
Ann Epidemiol; 2000 Feb; 10(2):125-34. PubMed ID: 10691066
[TBL] [Abstract][Full Text] [Related]
8. Salvage radical prostatectomy for radiation-recurrent prostate cancer: a multi-institutional collaboration.
Chade DC; Shariat SF; Cronin AM; Savage CJ; Karnes RJ; Blute ML; Briganti A; Montorsi F; van der Poel HG; Van Poppel H; Joniau S; Godoy G; Hurtado-Coll A; Gleave ME; Dall'Oglio M; Srougi M; Scardino PT; Eastham JA
Eur Urol; 2011 Aug; 60(2):205-10. PubMed ID: 21420229
[TBL] [Abstract][Full Text] [Related]
9. Lower prostate cancer risk in men with elevated plasma lycopene levels: results of a prospective analysis.
Gann PH; Ma J; Giovannucci E; Willett W; Sacks FM; Hennekens CH; Stampfer MJ
Cancer Res; 1999 Mar; 59(6):1225-30. PubMed ID: 10096552
[TBL] [Abstract][Full Text] [Related]
10. Prostate-specific antigen level, stage or Gleason score: which is best for predicting outcomes after radical prostatectomy, and does it vary by the outcome being measured? Results from Shared Equal Access Regional Cancer Hospital database.
Mithal P; Howard LE; Aronson WJ; Kane CJ; Cooperberg MR; Terris MK; Amling CL; Freedland SJ
Int J Urol; 2015 Apr; 22(4):362-6. PubMed ID: 25728968
[TBL] [Abstract][Full Text] [Related]
11. Predictors of biochemical recurrence after Retzius-sparing robot-assisted radical prostatectomy: Analysis of 359 cases with a median follow-up period of 26 months.
Abdel Raheem A; Chang KD; Alenzi MJ; Ham WS; Han WK; Choi YD; Rha KH
Int J Urol; 2018 Dec; 25(12):1006-1014. PubMed ID: 30276864
[TBL] [Abstract][Full Text] [Related]
12. Importance of Local Control in Early-Stage Prostate Cancer: Outcomes of Patients With Positive Post-Radiation Therapy Biopsy Results Treated in RTOG 9408.
Krauss DJ; Hu C; Bahary JP; Souhami L; Gore EM; Chafe SM; Leibenhaut MH; Narayan S; Torres-Roca J; Michalski J; Zeitzer KL; Donavanik V; Sandler H; McGowan DG; Jones CU; Shipley WU
Int J Radiat Oncol Biol Phys; 2015 Jul; 92(4):863-73. PubMed ID: 26104939
[TBL] [Abstract][Full Text] [Related]
13. Preoperative combined nested reverse transcriptase polymerase chain reaction for prostate-specific antigen and prostate-specific membrane antigen does not correlate with pathologic stage or biochemical failure in patients with localized prostate cancer undergoing radical prostatectomy.
Thomas J; Gupta M; Grasso Y; Reddy CA; Heston WD; Zippe C; Dreicer R; Kupelian PA; Brainard J; Levin HS; Klein EA
J Clin Oncol; 2002 Aug; 20(15):3213-8. PubMed ID: 12149293
[TBL] [Abstract][Full Text] [Related]
14. Safety and efficacy of the specific endothelin-A receptor antagonist ZD4054 in patients with hormone-resistant prostate cancer and bone metastases who were pain free or mildly symptomatic: a double-blind, placebo-controlled, randomised, phase 2 trial.
James ND; Caty A; Borre M; Zonnenberg BA; Beuzeboc P; Morris T; Phung D; Dawson NA
Eur Urol; 2009 May; 55(5):1112-23. PubMed ID: 19042080
[TBL] [Abstract][Full Text] [Related]
15. The role of adjuvant radiotherapy in pathologically lymph node-positive prostate cancer.
Jegadeesh N; Liu Y; Zhang C; Zhong J; Cassidy RJ; Gillespie T; Kucuk O; Rossi P; Master VA; Alemozaffar M; Jani AB
Cancer; 2017 Feb; 123(3):512-520. PubMed ID: 27859018
[TBL] [Abstract][Full Text] [Related]
16. Outcome According to Elective Pelvic Radiation Therapy in Patients With High-Risk Localized Prostate Cancer: A Secondary Analysis of the GETUG 12 Phase 3 Randomized Trial.
Blanchard P; Faivre L; Lesaunier F; Salem N; Mesgouez-Nebout N; Deniau-Alexandre E; Rolland F; Ferrero JM; Houédé N; Mourey L; Théodore C; Krakowski I; Berdah JF; Baciuchka M; Laguerre B; Davin JL; Habibian M; Culine S; Laplanche A; Fizazi K
Int J Radiat Oncol Biol Phys; 2016 Jan; 94(1):85-92. PubMed ID: 26576711
[TBL] [Abstract][Full Text] [Related]
17. Early salvage radiation therapy does not compromise cancer control in patients with pT3N0 prostate cancer after radical prostatectomy: results of a match-controlled multi-institutional analysis.
Briganti A; Wiegel T; Joniau S; Cozzarini C; Bianchi M; Sun M; Tombal B; Haustermans K; Budiharto T; Hinkelbein W; Di Muzio N; Karakiewicz PI; Montorsi F; Van Poppel H
Eur Urol; 2012 Sep; 62(3):472-87. PubMed ID: 22633803
[TBL] [Abstract][Full Text] [Related]
18. Percentage of positive biopsy cores: a better risk stratification model for prostate cancer?
Huang J; Vicini FA; Williams SG; Ye H; McGrath S; Ghilezan M; Krauss D; Martinez AA; Kestin LL
Int J Radiat Oncol Biol Phys; 2012 Jul; 83(4):1141-8. PubMed ID: 22099043
[TBL] [Abstract][Full Text] [Related]
19. The Role of Prostate-specific Antigen Persistence After Radical Prostatectomy for the Prediction of Clinical Progression and Cancer-specific Mortality in Node-positive Prostate Cancer Patients.
Bianchi L; Nini A; Bianchi M; Gandaglia G; Fossati N; Suardi N; Moschini M; Dell'Oglio P; Schiavina R; Montorsi F; Briganti A
Eur Urol; 2016 Jun; 69(6):1142-8. PubMed ID: 26749093
[TBL] [Abstract][Full Text] [Related]
20. Impact of surgical margin status on prostate-cancer-specific mortality.
Chalfin HJ; Dinizo M; Trock BJ; Feng Z; Partin AW; Walsh PC; Humphreys E; Han M
BJU Int; 2012 Dec; 110(11):1684-9. PubMed ID: 22788795
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
